Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 16, 2026, 11:14 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 577–600 of 813 matching trials from the live ClinicalTrials.gov search.
Conditions
Attention Deficit/Hyperactivity Disorder
Interventions
centanafadine capsule, placebo capsule
Drug · Other
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
4 Years to 12 Years
Enrollment
574 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
New York, New York
Completed Not applicable Interventional Accepts healthy volunteers

Lifestyle Enhancement for ADHD Program 2

NCT04779333
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
LEAP, Standard BMT
Behavioral
Lead sponsor
Seattle Children's Hospital
Other
Eligibility
6 Years to 10 Years
Enrollment
88 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
Seattle, Washington
Conditions
ADHD
Interventions
Solriamfetol Dose A, Solriamfetol Dose B, Placebo
Drug
Lead sponsor
Axsome Therapeutics, Inc.
Industry
Eligibility
12 Years to 17 Years
Enrollment
468 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
31
States / cities
Dothan, Alabama • Little Rock, Arkansas • Anaheim, California + 27 more
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
SPD465, Placebo
Drug · Other
Lead sponsor
Shire
Industry
Eligibility
19 Years to 25 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
1
States / cities
Tampa, Florida
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Network Control TMS fMRI

NCT05736458
Conditions
Attention Deficit Hyperactivity Disorder, Attention Deficit Disorder, Working Memory
Interventions
Transcranial Magnetic Stimulation (TMS), High controllability TMS target
Device · Procedure
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 28 Years
Enrollment
68 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

How Virtual Reality Can Help Neurodivergent Children Improve Their Attention

NCT07341204
Conditions
Autism, Autism Disorder, ADHD - Attention Deficit Disorder With Hyperactivity, Attention Deficit Disorder
Interventions
Virtual Reality
Behavioral
Lead sponsor
New York Institute of Technology
Other
Eligibility
9 Years to 18 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Old Westbury, New York
Conditions
Attention-Deficit Hyperactivity Disorder
Interventions
Lisdexamfetamine Dimesylate (LDX), Immediate Release Mixed Amphetamine Salts (MAS-IR), LDX Placebo + MAS-IR Placebo
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years to 55 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
1
States / cities
Houston, Texas
Conditions
ADHD
Interventions
EWM Training, Placebo Training
Behavioral
Lead sponsor
Hartford Hospital
Other
Eligibility
12 Years to 18 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Hartford, Connecticut
Conditions
Attention Deficit Disorder With Hyperactivity
Interventions
Lobeline sulfate, Methylphenidate HCl, Placebo
Drug
Lead sponsor
Yaupon Therapeutics
Industry
Eligibility
21 Years to 45 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Lexington, Kentucky
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Sensory-Play Based (SenPlay) Intervention, Spontaneous, Free Play
Other
Lead sponsor
University of Oklahoma
Other
Eligibility
36 Months to 71 Months
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Yukon, Oklahoma
Completed Not applicable Interventional Results available

Skills Training for Adolescents With ADHD

NCT01019252
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Cognitive Behavioral Therapy (CBT)
Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
14 Years to 18 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Attention Deficit Disorder With Hyperactivity, Epilepsy
Interventions
Extended Release Methylphenidate (OROS-Methylphenidate)
Drug
Lead sponsor
Boston Children's Hospital
Other
Eligibility
6 Years to 18 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
1
States / cities
Boston, Massachusetts
Recruiting Not applicable Interventional Accepts healthy volunteers

A Pilot Study of a Remote ADHD Monitoring Program

NCT06743425
Conditions
Attention-deficit/Hyperactivity Disorder, ADHD
Interventions
RAMP Reports, Digital Education Handouts
Other
Lead sponsor
IDeA States Pediatric Clinical Trials Network
Network
Eligibility
5 Years to 11 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
2
States / cities
Jackson, Mississippi • Charleston, South Carolina
Completed Phase 2 Interventional Results available

Shire SCT: Lisdexamfetamine Treatment for ADHD and SCT

NCT02635035
Conditions
Attention Deficit Disorder, Attention Deficit Hyperactivity Disorder
Interventions
Lisdexamfetamine, Placebo
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 60 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
2
States / cities
New York, New York
Conditions
ADHD
Interventions
Vayarin, Placebo
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years to 60 Years
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
New York, New York
Conditions
ADHD
Interventions
Behavioral Parenting Intervention
Behavioral
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
5 Years to 12 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
1
States / cities
Hershey, Pennsylvania
Completed Phase 4 Interventional Results available

CONCERTA Lab School Study

NCT00799487
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
CONCERTA (methylphenidate HCl) or placebo
Drug
Lead sponsor
Ortho-McNeil Janssen Scientific Affairs, LLC
Industry
Eligibility
9 Years to 12 Years
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
3
States / cities
Little Rock, Arkansas • Las Vegas, Nevada • Durham, North Carolina
Conditions
ADHD, Cancer
Interventions
Not listed
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
12 Years to 17 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Memphis, Tennessee
Conditions
Adult Attention Deficit Hyperactivity Disorder
Interventions
Serdexmethylphenidate/dexmethylphenidate
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 60 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
New York, New York
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Atomoxetine hydrochloride, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 30 Years
Enrollment
445 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
27
States / cities
Los Angeles, California • Rolling Hills Est., California • Spring Valley, California + 24 more
Conditions
Attention Deficit Disorder With Hyperactivity, HIV Infections, Paralysis
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2000
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
AKL-T01
Device
Lead sponsor
Akili Interactive Labs, Inc.
Industry
Eligibility
13 Years to 17 Years
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
14
States / cities
Scottsdale, Arizona • San Diego, California • Maitland, Florida + 10 more
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
ADZENYS XR-ODT, Placebo Oral Tablet
Drug
Lead sponsor
Aytu BioPharma, Inc.
Industry
Eligibility
4 Years to 5 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Las Vegas, Nevada
Conditions
Traumatic Brain Injury
Interventions
methylphenidate, Placebo
Drug
Lead sponsor
Uniformed Services University of the Health Sciences
Federal
Eligibility
18 Years to 55 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland